Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2008; 133(19): 1009-1020
DOI: 10.1055/s-2008-1075687
DOI: 10.1055/s-2008-1075687
CME-Beitrag | Review article
Pneumologie, Kardiologie, Angiologie
© Georg Thieme Verlag KG Stuttgart · New York
Pulmonal arterielle Hypertonie
Pulmonary arterial hypertensionFurther Information
Publication History
eingereicht: 11.2.2008
akzeptiert: 24.4.2008
Publication Date:
29 April 2008 (online)
Schlüsselwörter
pulmonale Hypertonie - pulmonal arterielle Hypertonie - Endothelin-Rezeptor-Antagonisten - Prostanoide - Phosphodiesterase 5-Inhibitoren
Key words
pulmonary hypertension - pulmonary arterial hypertension - endothelin receptor antagonists - prostanoids - phosphodiesterase type 5 inhibitors
Literatur
- 1 Badesch D B, Abman S H, Ahearn G S. et al . Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126 (Suppl 1) 35S-S62
- 2 Badesch D B, Tapson V F, McGoon M D. et al . Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. Ann Intern Med. 2000; 132 425-434
- 3 Barst R J, McGoon M, Torbicki A. et al . Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004; 43 40S-47S
- 4 Barst R J, Rubin L J, Long W A. et al . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996; 334 296-302
- 5 Bossone E, Bodini B D, Mazza A, Allegra L. Pulmonary arterial hypertension: The key role of echocardiography. Chest. 2005; 127 1836-1843
- 6 Channick R N, Simmoneau G, Sitbon. et al . Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension. Lancet. 2001; 358 1119-1123
- 7 Chaouat A, Bugnet A -S, Kadaoui N. et al . Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 172 189-194
- 8 Currie P J, Seward J B, Chan K L. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol. 1985; 6 750-756
- 9 D’Alonzo G E, Barst R J, Ayres S M. et al . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115 343-9
- 10 Denton C, Cailes J, Phillips G, Wells A, Black C, Du B ois M. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997; 36 239-243
- 11 Fijalkowska A, Kurzyna M, Torbicki A. et al . Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest. 2006; 129 1313-1321
- 12 Forfia P R, Fisher M R, Mathai S C. et al . Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Resp Crit Care Med. 2006; 174 1034-1041
- 13 Galié N, Torbicki A, Barst R. et al . Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J. 2004b; 25 2243-78
- 14 Ghofrani H A, Wiedemann R, Rose F. et al . Sildenafil for the treatment of lung fibrosis and pulmonary hypertension: A randomized controlled trial. Lancet. 2002; 360 895-900
- 15 Ghofrani H A, Wiedemann R, Rose F. et al . Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002; 136 515-522
- 16 Hertz M I, Taylor D O, Trulock E P. et al . The registry of the International Society for Heart and Lung Transplantation: Nineteenth official report 2002. J Heart Lung Transplant. 2002; 21 950-970
- 17 Höper M M, Markevych I, Spiekerkötter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J. 2005; 26 858-863
- 18 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial arterial hypertension. N Engl J Med. 2004b; 351 1425-1436
- 19 Kaul S, Tei C, Hopkins J M, Shah P M. Assessment of right ventricular function using two-dimensional echocardiography. Am Heart J. 1984; 107 526-531
- 20 Magnussen H, Goeckenjan G, Kohler D. et al . [Guidelines to long-term oxygen therapy]. Pneumologie. 2001; 55 454-464
- 21 McGoon M, Gutterman D, Steen V. et al . Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126 (Suppl 1) 14S-34S
- 22 McLaughlin V V, Sitbon O, Badesch D B. et al . Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005; 25 244-249
- 23 Mereles D, Ehlken N, Kreuscher S. et al . Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation. 2006; 114 1482-1489
- 24 Nagaya N, Nishikimi T, Uematsu M. et al . Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000; 102 865-870
- 25 Newman J H, Trembath R C, Morse J A. et al . Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004; 43 (12 Suppl S) 33S-39S
- 26 Olschewski H, Höper M M, Borst M M. et al . Diagnostik und Therapie der chronischen pulmonalen Hypertonie. Clin Res Cardiol. 2007; 96 301-330
- 27 Olschewski H, Simmoneau G, Galié N. et al, Aerosolized Iloprost Randomized Study Group . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002; 347 322-329
- 28 Oudiz R J. The role of exercise testing in the management of pulmonary arterial hypertension. Sem Respir Crit Care Med. 2005; 26 379-384
- 29 Raymond R J, Hinderliter A L, Willis P W. et al . Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002; 39 1214-1219
- 30 Rich S, Kaufmann E, Levy P S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992; 327 76-81
- 31 Rosenkranz S, Diet F, Karasch T, Weihrauch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med. 2003; 139 871-873
- 32 Rubin L J, Badesh D B, Barst R J. et al . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346 896-903
- 33 Sandoval J, Gaspar J, Pulido T. et al . Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. J Am Coll Cardiol. 1998; 32 297-304
- 34 Sastry B K, Narasimhan C, Reddy N K, Raju B S. Clinical efficacy of sildenafil in primary pulmonary hypertension. J Am Coll Cardiol. 2004; 43 1149-1153
- 35 Simonneau G, Barst R J, Galie N. et al . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165 800-804
- 36 Simonneau G, Galié N, Rubin L. et al . Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004; 43 (Suppl 1) 5S-12S
- 37 Sitbon O, Humbert M, Jais X. et al . Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005; 111 3105-3111
- 38 Sun X G, Hansen J E, Oudiz R J. et al . Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. 2001; 104 429-435
- 39 Tei C, Dujardin K S, Hodge D O. et al . Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr. 1996; 9 838-847
- 40 Wensel R, Opitz C F, Anker S D. et al . Assessment of survival in patients with primary pulmonary hypertension. Importance of cardiopulmonary exercise testing. Circulation. 2002; 106 319-324
- 41 Wilkens H, Guth A, Konig J. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001; 104 1218-1222
- 42 Yasunobu Y, Oudiz R J, Sun X G, Hansen J E, Wasserman K. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest. 2005; 127 1637-1646
Priv.-Doz. Dr. med. Stephan Rosenkranz
Klinik III für Innere Medizin, Zentrum für Molekulare Medizin Köln (ZMMK), Klinikum der Universität zu Köln
Kerpener Str. 62
50937 Köln
Email: stephan.rosenkranz@uk-koeln.de